RxDoctor Payments Data

Enrico Novelli, MD

Internal Medicine · Pittsburgh, PANPI 1033243639

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $137,616 of the $175,959 with a category attached, or 78.2%. Novo Nordisk Health Care AG accounts for 85.4% of it on its own, with 5 other manufacturers making up the rest. Among internal medicine clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$175,959in general payments, 2019–2025

Across 41 payments — averaging $4291.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk Health Care AG$150K
  • Novo Nordisk$13K
  • Shield Therapeutics Inc$6K
  • Chiesi USA, Inc.$4K
  • Novartis$2K
  • Vertex$42
$220,998in research payments, 2019–2025

Across 62 payments — averaging $3564.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Agios Pharmaceuticals, Inc.$216K
  • Novartis$5K

What the payments were for

  • Consulting fees$137,61678%
  • Speaking & faculty fees$10,0706%
  • Travel & lodging$26,53715%
  • Food & beverage$1,7361%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk Health Care AG28$150,295
Novo Nordisk4$13,125
Shield Therapeutics Inc4$6,294
Chiesi USA, Inc.1$3,915
Novartis3$2,288
Vertex1$42

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$175,959 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$6,371
Medicare patients
38
Services billed
54

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl42$31,963
Enoxaparin Sodium15$6,551
Hydromorphone Hcl31$1,501
Oxycodone Hcl23$422
Warfarin Sodium18$316
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen17$192

Paid to pharmacies, not to this prescriber.

Other internal medicine in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →